Serono
| Merck Serono | ||
|---|---|---|
 |
||
| Type | Stock corporation | |
| 1906 | ||
| Location | Geneva, Switzerland (Headquarters) | |
| Key people |
Ernesto Bertarelli CEO |
Claudio Bertarelli Chairman of the Board |
| Industry | Biotechnology / Pharmaceutical | |
| Key Products | Rebif, Gonal-f, Luveris, Ovidrel/Ovitrelle, Serostim, Saizen, Zorbtive and Raptiva | |
| Revenue | USD ~5.9 billion (2014) | |
| Website | www |
|
Serono was a biotechnology company headquartered in Geneva, Switzerland. The company was founded as the Serono Pharmacological Institute by Cesare Serono in 1906 in Italy. A key step in its development was the discovery of a method of extracting urinary gonadotropins by Dr Piero Donini. Serono was incorporated in 1987 and the holding company, Ares-Serono S.A., changed its name to Serono S.A. in May 2000.
Serono as a stand-alone company develops and markets pharmaceuticals in the fields of , Multiple Sclerosis, Growth & Metabolism and Dermatology. It holds an estimated market share of 60%, making it the third largest biotechnology company in the world. Serono's most important product accounted for 31.6% of the company's sales in 2004.
The eight biotechnology products are available in four core therapeutic areas: neurology for the treatment of relapsing forms of multiple sclerosis, for treatments of infertility, dermatology, where Serono has launched biologics in Europe for moderate-to-severe psoriasis, and growth and metabolism for treatments for HIV-associated wasting and growth deficiencies.
The Company also conducts research in oncology and autoimmune diseases. Through the acquisition in 1997 of GBRI from GlaxoWelcome, becoming its Geneva based research institute named SPRI, and the Manteia Predictive Medicine spin-off, Serono also nursed the emergence of now a commercial leading massive parallel sequencing technology.
...
Wikipedia